Hikma Pharmaceuticals (OTCMKTS:HKMPF) Trading 3.7% Higher – Should You Buy?

Posted by Jeff Wilder on Jan 3rd, 2025

Hikma Pharmaceuticals PLC (OTCMKTS:HKMPF – Get Free Report) shares were up 3.7% during trading on Friday . The stock traded as high as $25.02 and last traded at $25.02. Approximately 3,835 shares changed hands during mid-day trading, an increase of 1,146% from the average daily volume of 308 shares. The stock had previously closed at $24.12.

Analyst Ratings Changes

Separately, Royal Bank of Canada raised Hikma Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Tuesday, December 10th.

Check Out Our Latest Analysis on HKMPF

Hikma Pharmaceuticals Trading Up 3.7 %

The business has a fifty day moving average of $24.19 and a 200-day moving average of $24.81. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.66 and a quick ratio of 0.98.

Hikma Pharmaceuticals Company Profile

(Get Free Report)

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.